Drug Combination Details
| General Information of the Combination (ID: C57420) | |||||
|---|---|---|---|---|---|
| Name | Arctigenin NP Info | + | Doxorubicin Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Breast cancer
[ICD-11: 2C60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Decreasing Adverse Drug Reaction by This Combination | ||||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Expression | STAT3 | Molecule Info |
Pathway MAP
|
|
| In-vitro Model | MDA-MB-231 | CVCL_0062 | Breast adenocarcinoma | Homo sapiens | ||
| Experimental
Result(s) |
ATG might alleviate the side effects and improve the therapeutic efficacy of DOX. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Arctigenin Enhances the Cytotoxic Effect of Doxorubicin in MDA-MB-231 Breast Cancer Cells. Int J Mol Sci. 2020 Apr 23;21(8):2997. | |||
